Novel Bifunctional Conjugates Targeting PD-L1/PARP7 as Dual Immunotherapy for Potential Cancer Treatment
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Yuan Gao und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hangzhou Normal University, Zhejiang, Hangzhou 311121, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Antineoplastic Agents, Immunotherapy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: High-end Foreign Experts Recruitment Plan of China, Science and Technology Department of Zhejiang Province, Medical Science and Technology Project of Zhejiang Province.
Abstract (Originalsprache)
Bifunctional conjugates targeting PD-L1/PARP7 were designed, synthesized, and evaluated for the first time. Compounds B3 and C6 showed potent activity against PD-1/PD-L1 interaction (IC50 = 0.426 and 0.342 μM, respectively) and PARP7 (IC50 = 2.50 and 7.05 nM, respectively). They also displayed excellent binding affinity with hPD-L1, approximately 100-200-fold better than that of hPD-1. Both compounds restored T-cell function, leading to the increase of IFN-γ secretion. In the coculture assay, B3 and C6 enhanced the killing activity of MDA-MB-231 cells by Jurkat T cells in a concentration-dependent manner. Furthermore, B3 and C6 displayed significant in vivo antitumor efficacy in a melanoma B16-F10 tumor mouse model, more than 5.3-fold better than BMS-1 (a PD-L1 inhibitor) and RBN-2397 (a PARP7i clinical candidate) at the dose of 25 mg/kg, without observable side effects. These results provide valuable insight and understanding for developing bifunctional conjugates for potential anticancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Hangzhou Normal University, Zhejiang, Hangzhou 311121, China.
- Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of…
- Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, China.
- College of Life and Environmental Sciences, Hangzhou Normal University, Zhejiang, Hangzhou 311121, China.
ORCID-Profile: Xiang-Yang Ye
Förderung
- High-end Foreign Experts Recruitment Plan of China
- Science and Technology Department of Zhejiang Province
- Medical Science and Technology Project of Zhejiang Province
- Hangzhou Science and Technology Bureau
- Zhejiang Provincial Xinmiao Talents Program
Zitieren
APA
Gao, Y., Duan, J. L., Wang, C. C., Yuan, Y., Zhang, P., Wang, Z. H., Sun, B., Zhou, J., Du, X., Dang, X., Bai, R. T., Zhang, H., Xie, T., & Ye, X. Y. (2024). Novel Bifunctional Conjugates Targeting PD-L1/PARP7 as Dual Immunotherapy for Potential Cancer Treatment. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00296
Vancouver
Gao Y, Duan JL, Wang CC, Yuan Y, Zhang P, Wang ZH, et al. Novel Bifunctional Conjugates Targeting PD-L1/PARP7 as Dual Immunotherapy for Potential Cancer Treatment. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00296
BibTeX
@article{Gao2024,
author = {Gao, Yuan and Duan, Ji-Long and Wang, Chen-Chen and Yuan, Yinghui and Zhang, Pengpeng and Wang, Zong-Hao and Sun, Bowen and Zhou, Jiawei and Du, Xiaoli and Dang, Xiawen and Bai, Rui-Ting and Zhang, Hang and Xie, Tian and Ye, Xiang-Yang},
title = {Novel Bifunctional Conjugates Targeting PD-L1/PARP7 as Dual Immunotherapy for Potential Cancer Treatment},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00296}
}
EUVIMED